GlassScriptPhysician profile
Christopher James Lane
NPI 1063987303
$2,618.56
in general payments reported to CMS, 2019-2025
33 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $999 · 2022: $420 · 2023: $510 · 2024: $381 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,175 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.99 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $550.27 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $285.95 | 2021-2025 | |
| Lilly USA, LLC | $171.73 | 2021-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $168.85 | 2021-2023 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $126.70 | 2021-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $124.58 | 2021-2025 | Shingrix, Arexvy |
| Pfizer INC. | $123.80 | 2023-2025 | |
| Amgen INC. | $121.71 | 2021-2025 | Otezla, Repatha, Evenity |
| Exact Sciences Corporation | $84.12 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $80.23 | 2021-2025 | Spravato |
| Medtronic, INC. | $62.03 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Biohaven Pharmaceutical Holding Company LTD. | $61.11 | 2022 | |
| Sanofi-Aventis U.S. LLC | $58.86 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $53.95 | 2021-2023 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $53.55 | 2023-2024 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $50.51 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.56 | 2021-2022 | |
| Daiichi Sankyo INC. | $47.02 | 2021-2022 | |
| Axsome Therapeutics, INC. | $38.02 | 2024 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $37.85 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $34.69 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $29.44 | 2021 | |
| Merck Sharp & Dohme LLC | $27.34 | 2022 | |
| Kyowa Kirin, INC. | $23.20 | 2024 | Crysvita |
| Esperion Therapeutics, INC. | $22.05 | 2021 | |
| Genzyme Corporation | $20.24 | 2024 | |
| Bausch Health US, LLC | $19.41 | 2021 | |
| Nestle Healthcare Nutrition INC. | $17.62 | 2022 | |
| Nevro Corp. | $17.20 | 2024 | Senza |
| Dexcom, INC. | $16.80 | 2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $14.93 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.09 | 2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $12.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.